ClinicaliQ Trial Snapshot
- Stopping PPI Therapy in Inactive IBD — Recruiting • Phase IV • Rheumatology • NCT07691138.
- What is being tested: The feasibility and safety of withdrawing proton pump inhibitor (PPI) therapy in patients with inactive inflammatory bowel disease (IBD), with the aim of informing design of a future large-scale randomised controlled trial.
- Patient eligibility overview: Adults with confirmed IBD (Crohn's disease or ulcerative colitis) in clinical remission who are currently receiving PPI therapy, with adequate disease monitoring and access to follow-up care.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
To investigate the feasibility of proton pump inhibitor (PPI) withdrawal in inflammatory bowel disease (IBD); the data collected will provide valuable information to inform a future multi-centre randomised controlled trial. Evidence suggests that patients with IBD taking PPIs respond less well to medication and require hospital treatment more frequently than patients not taking PPIs. This may be due to changes in the gut microbiota associated with PPI use. A future definitive trial is planned to investigate clinical outcomes in patients who stop PPIs compared with those who continue PPIs, in…
Eligibility Snapshot
- : * Aged 16 years or older. * An IBD diagnosis as defined through SNOMED codes in primary care databases [Appendix 5] * Taking a PPI regularly for >6 months prior to enrolment * Patient-confirmed compliance with PPI therapy (>75% of prescribed doses) * Able to give full, independent valid Informed consent * Stable disease as defined by no change in medication or IBD-related surgery for the last 3 months.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.